These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9566765)

  • 1. Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity.
    Jrad BB; Bahraoui E
    Mol Immunol; 1997; 34(16-17):1177-89. PubMed ID: 9566765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification.
    Belhadj Jrad B; Bahraoui E
    J Pept Res; 1998 May; 51(5):370-85. PubMed ID: 9606017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of B-cell antigenic sites on HIV-2 gp125.
    Mannervik M; Putkonen P; Rudén U; Kent KA; Norrby E; Wahren B; Broliden PA
    J Acquir Immune Defic Syndr (1988); 1992; 5(2):177-87. PubMed ID: 1370692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125.
    Campbell AP; Sykes BD; Norrby E; Assa-Munt N; Dyson HJ
    Fold Des; 1996; 1(2):157-65. PubMed ID: 9079375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
    Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
    Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
    Björling E; Broliden K; Bernardi D; Utter G; Thorstensson R; Chiodi F; Norrby E
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6082-6. PubMed ID: 2068087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.
    Björling E; Chiodi F; Utter G; Norrby E
    J Immunol; 1994 Feb; 152(4):1952-9. PubMed ID: 8120399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
    Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
    FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
    Meyer D; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of anti-peptide antibodies elicited against synthetic peptides mimicking conserved regions of HIV1 envelope glycoprotein.
    Clerget-Raslain B; Benjouad A; van Rietschoten J; Montagnier L; Rochat H; Bahraoui E
    Res Virol; 1991; 142(6):423-38. PubMed ID: 1803410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
    Kelker HC; Schlesinger D; Valentine FT
    J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 15. Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display.
    Björling E; von Garrelts E; Mörner A; Ehnlund M; Persson MAA
    J Gen Virol; 1999 Aug; 80 ( Pt 8)():1987-1993. PubMed ID: 10466795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.
    Lizeng Q; Skott P; Sourial S; Nilsson C; Andersson S S; Ehnlund M; Taveira N; Björling E
    Virology; 2003 Apr; 308(2):225-32. PubMed ID: 12706073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
    Neurath AR; Strick N; Fields R; Jiang S
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.